ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2157

Evaluation of Functional Disability over Time in the Leiden Systemic Sclerosis (CCISS) Cohort
Abstract Number: 2158

A Decade of Caring for SSc Patients: Do Outcomes Improve? Data from the Leiden CCISS Cohort
Abstract Number: 2159

Gastroesophageal Reflux Disease in an Australian Scleroderma Cohort – Associations and Effect of Treatment
Abstract Number: 2160

The Role of CCL21 in Serum Samples from Systemic Sclerosis Patients
Abstract Number: 2161

Alterations of Nutritional Status of Scleroderma Patients and Associations with Disease-specific Features
Abstract Number: 2162

Systemic Sclerosis in Alaska Native/American Indian People in Alaska
Abstract Number: 2163

Lipid Profile in Scleroderma Patients and the Associations of Its Changes with Disease-specific Features
Abstract Number: 2164

Profibrotic Alveolar Macrophages as a Potential Biomarker in Systemic Sclerosis-associated Interstitial Lung Disease
Abstract Number: 2165

Patients with Systemic Sclerosis Have Impaired Forced Vital Capacity, Even in the Absence of Interstitial Lung Disease
Abstract Number: 2166

Inflammatory Arthritis in an Australian Scleroderma Cohort – Patient Characteristics, Associations and Treatments
Abstract Number: 2167

Autoantibodies in Patients with Early Systemic Sclerosis in the Collaborative National Quality and Efficacy Registry
Abstract Number: 2168

A Novel Pharmaco-Interventional Approach for the Treatment of Refractory Digital Ischemia in Systemic Sclerosis – Percutaneous Revascularization Combined with Intravenous Vasodilatory Therapy
Abstract Number: 2169

Cardiac Rhythm and Conduction Abnormalities in Systemic Sclerosis-meta-analysis
Abstract Number: 2170

Validation of Ranked Composite Important Difference (RCID) Score in Early Diffuse Cutaneous Systemic Sclerosis
Abstract Number: 2171

Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous Systemic Sclerosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].